Leerink Partnrs Reduces Earnings Estimates for Moderna

Moderna, Inc. (NASDAQ:MRNA) – Research analysts at Leerink Partnrs decreased their FY2024 earnings estimates for shares of Moderna in a research note issued on Monday, January 13th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($9.61) for the year, down from their prior forecast of ($9.50). The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share. Leerink Partnrs also issued estimates for Moderna’s Q4 2024 earnings at ($3.28) EPS, Q1 2025 earnings at ($2.58) EPS, Q2 2025 earnings at ($2.56) EPS, Q3 2025 earnings at ($2.55) EPS, FY2025 earnings at ($10.28) EPS, FY2026 earnings at ($7.73) EPS and FY2027 earnings at ($4.13) EPS.

MRNA has been the topic of several other reports. Sanford C. Bernstein assumed coverage on shares of Moderna in a research note on Thursday, October 17th. They issued a “market perform” rating and a $55.00 target price on the stock. Bank of America reissued an “underperform” rating and issued a $41.00 price target on shares of Moderna in a report on Tuesday, December 10th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 price objective on shares of Moderna in a research note on Thursday, September 19th. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Four equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $75.58.

Moderna Price Performance

Shares of Moderna stock opened at $33.76 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna has a one year low of $31.94 and a one year high of $170.47. The business’s 50 day simple moving average is $41.11 and its two-hundred day simple moving average is $67.32. The stock has a market capitalization of $12.99 billion, a P/E ratio of -5.80 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.39) earnings per share.

Insider Buying and Selling

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 2,664 shares of company stock worth $115,210 in the last three months. 15.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Axiom Advisory LLC grew its stake in shares of Moderna by 1.6% in the third quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock worth $847,000 after acquiring an additional 198 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in Moderna during the 2nd quarter valued at about $26,000. Arkadios Wealth Advisors increased its stake in Moderna by 2.2% during the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock valued at $764,000 after purchasing an additional 243 shares in the last quarter. Knuff & Co LLC increased its stake in Moderna by 5.4% during the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after purchasing an additional 244 shares in the last quarter. Finally, Stephens Inc. AR raised its holdings in Moderna by 7.9% in the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after buying an additional 245 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.